Clinical Trial: Follow-up of Pediatric Patients Affected by Primary Hyperoxaluria Type 1 (PH1) Treated With Lumasiran

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07874074) titled 'Follow-up of Pediatric Patients Affected by Primary Hyperoxaluria Type 1 (PH1) Treated With Lumasiran' on Oct. 08.

Brief Summary: The primary objective of the study is to confirm, in pediatric patients with type 1 hyperoxaluria treated with Lumasiran, the reduction in urinary oxalate excretion and plasma oxalate levels-already described at six months-on a larger number of patients and with an extended follow-up (1-5 years), and to evaluate in the same patients the ultrasound-detected reduction in the number of kidney stones over time from the initiation of treatment.

Study Start Date: July 06, 2022

Study Type: OBSERVATIONAL

Condi...